Business Context and Reporting Period
Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. In November 2025, the Company changed its name and trading symbol to "CYPH" to reflect a strategic pivot. The Company now operates a dual strategy: (1) a digital asset treasury strategy focused on accumulating Zcash (ZEC) to advance privacy technology, and (2) continued biotechnology operations through its wholly-owned subsidiary, Leap Therapeutics, Inc., developing cancer therapies.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Income (Loss) | $4.8 million | ($67.6 million) |
| Operating Expenses | $41.1 million | $70.1 million |
| Research & Development | $25.7 million | $57.2 million |
| Cash and Cash Equivalents | $14.0 million | $47.2 million |
| Digital Assets Receivable (ZEC) | $147.4 million | $0 |
| Total Assets | $163.2 million | $49.1 million |
| Accumulated Deficit | ($462.5 million) | ($467.4 million) |
Key Drivers: The 2025 net income was primarily driven by a $50.4 million unrealized gain on the change in fair value of the embedded derivative associated with ZEC holdings. Operating expenses decreased significantly due to the completion of clinical trials and a reduction in workforce.
Material Changes vs. Prior Period
- Strategic Pivot: Shifted from a pure-play biotech firm to a hybrid privacy technology and digital asset treasury company. Initiated accumulation of Zcash in October 2025.
- Asset Composition: Digital assets now represent approximately 90% of total assets ($147.4 million), compared to zero in 2024.
- Cost Reduction: Research and Development expenses dropped by 55% ($31.5 million) due to the wind-down of certain clinical activities and a reduction in force impacting ~75% of the workforce. Restructuring charges of $4.5 million were recorded.
- Financing: Raised approximately $108.7 million in net proceeds during 2025 through a private placement led by Winklevoss Capital and an At-The-Market (ATM) offering.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management believes cash and cash equivalents of $14.0 million are sufficient to fund operations for at least 12 months. The Company intends to continue accumulating ZEC, with a stated objective of holding at least 5% of the total circulating supply over time. No specific financial guidance for 2026 was provided.
Material Risks
- ZEC Volatility: The Company's financial results are highly sensitive to ZEC price fluctuations. A significant decline could materially adversely affect the balance sheet and stock price.
- Regulatory Uncertainty: Privacy-focused digital assets face potential regulatory bans (e.g., EU regulations effective July 2027) and scrutiny regarding money laundering and sanctions compliance.
- Custody Risk: All ZEC holdings are custodied by Gemini Space Station, LLC, an affiliate of lead investor Winklevoss Capital. This creates concentration and counterparty risk.
- Nasdaq Compliance: The Company received a deficiency letter from Nasdaq on March 4, 2026, for failing to maintain a $1.00 closing bid price. It has 180 days to regain compliance, potentially via a reverse stock split.
Unusual Items
- Material Weakness in Internal Controls: Management identified a material weakness in internal control over financial reporting related to the accounting for complex digital asset transactions. Remediation efforts are underway.
- Related Party Transactions: The Company purchased ZEC through Gemini, an affiliate of its lead investor, and invested $5 million in Zcash Open Development Lab (ZODL) in March 2026.
Investor Verification Checklist
- ZEC Valuation: Verify the current market price of ZEC and its impact on the $147.4 million asset valuation, given the high volatility noted in subsequent events.
- Custody Arrangements: Review the specific terms of the custodial agreement with Gemini and the implications of the related-party relationship with Winklevoss Capital.
- Nasdaq Status: Monitor the Company's progress in regaining compliance with Nasdaq's $1.00 minimum bid price requirement to avoid delisting.
- Internal Controls: Assess the progress of remediation for the identified material weakness in internal controls over financial reporting.
- Liquidity Runway: Confirm the $14.0 million cash balance is sufficient to cover operating expenses, given the lack of product revenue and ongoing R&D costs.